The submission period for ACT is now closed. Thank you for your Letters of Intent.
The Academic Clinical Trials Program (ACT) program is the newest program in the LLS Research portfolio. It is intended to enhance the development and implementation of academic investigator initiated clinical trials (IIT) in the hematological malignancy space.
The primary focus is IT Phase 1 or 2 trials investigating novel agents in any hematological disease either as single agents or in combination therapies. We are seeking truly novel advances and not simply incremental advances of existing agents.
Description of the Award
- The focus of the research must be a clinical trial.
- Additional aims can address topics such as correlative studies, biomarker investigations, etc.
- Repurposing of existing agents into novel diseases will also be considered.
- LLS is seeking truly novel advances and not simply incremental advances of existing agents.
- Existing trials or expansion of existing trials are eligible to apply.
Maximum ACT Award Duration & Value
- Maximum duration: 3 years
- Maximum total award: up to $1M*
- Maximum annual indirect costs: 15% of annual costs
*The final budget for these awards will be determined based on the amount requested in the application and is subject to change by LLS prior to signing the funding agreement.
How to apply
- Please refer to the Guidelines & Instructions document above
- Is this your first time applying for an LLS Research grant? You can get started by requesting a new account in the LLS Research Portal by clicking here.
- See the table below for all the key dates and deadlines:
2022-2023 Application Key Dates
|Call for Proposals||August 29, 2022|
|Letter of Intent Due||October 28, 2022, 3:00 PM ET|
|Full Application Due||January 17, 2023, 3:00 PM ET|
|Panel Review Meeting||Mid-March 2023|
|Award Notification||May 2023|
|Award Start Date||July 1, 2023|
Do you have any questions?
Please refer to the downloadable Guidelines and Instructions document above for answers and for contact information.